Latest

Tempus AI Delivers Exceptional Q2 2026 Results, Bolstered by Strong Growth in Diagnostics Business and Significant Milestones in Data and Modeling Capabilities

TEM

Tempus AI Delivers Exceptional Q2 2026 Results, Bolstered by Strong Growth in Diagnostics Business and Significant Milestones in Data and Modeling Capabilities

Tempus AI, a leading provider of artificial intelligence and machine learning solutions for the healthcare industry, today reported exceptional second quarter (Q2) 2026 results, driven by strong growth in its diagnostics business and significant milestones in its data and modeling capabilities. In a conference call to discuss its Q2 2026

By Julian Westcott
Cerus Corporation Surpasses 24 Million Transfusible Doses Produced Worldwide, Demonstrates Solid Progress Across Growth, Innovation, and Financial Priorities

CERS

Cerus Corporation Surpasses 24 Million Transfusible Doses Produced Worldwide, Demonstrates Solid Progress Across Growth, Innovation, and Financial Priorities

Cerus Corporation, a leading provider of blood safety solutions, has made significant strides in its mission to expand patient access to safe blood worldwide. During the second quarter of 2026, the company produced nearly 24 million transfusible doses globally, marking substantial progress towards its goal. According to Vivek Jayaraman, Cerus&

By Julia Horowitz